Gene Editing

Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression

Posted on January 3, 2023 by Editorial Staff

Researchers presented the results of a phase III randomized controlled trial of oral SARS-CoV-2 antiviral VV116.

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='facebook' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/facebook.svg'>

Share on Facebook

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='Twitter' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/Twitter.svg'>

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='Follow' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/Follow.png'>

<img alt='' src='https://secure.gravatar.com/avatar/008c46a8d463cb955213048824ccf788?s=90&d=identicon&r=g' srcset='https://secure.gravatar.com/avatar/008c46a8d463cb955213048824ccf788?s=180&d=identicon&r=g 2x' class='avatar avatar-90 photo' height='90' width='90' decoding='async'/>

Editorial Staff